Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

Tocilizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Rheumatoid Arthritis. According to GlobalData, Pre-Registration drugs for Rheumatoid Arthritis ...

The tool also features a built-in AI checker, ensuring that the humanized content is undetectable and authentic. BypassGPT is an effective AI humanizer tailored for those seeking to bypass AI ...

Inhibitors of IL-6 action can target either the IL-6 ligand itself or the IL-6 receptor. Tocilizumab is a humanized monoclonal antibody targeting the IL-6 receptor that was approved by the FDA in 2010 ...

2 Avtozma, a biosimilar referencing RoActemra ® (tocilizumab), has been recommended for all indications of its reference product, including moderate to severely active rheumatoid arthritis (RA ...